Pharmaco - Press Releases

Date	Title	Company
05-Oct-2021	Secarna Pharmaceuticals announces publication of new preclinical data showing strong potential of LNAplus(TM)-based ASOs to effectively treat diabetic kidney disease	Secarna Pharmaceuticals GmbH & Co. KG
05-Oct-2021	Heiner Dreismann Joins Noscendo’s Board of Directors	B3C newswire
05-Oct-2021	iOmx Therapeutics raises EUR 65 million in Series B round	iOmx Therapeutics AG
05-Oct-2021	Gisèle Deblandre Joins Cellbox Solutions as CSO	B3C newswire
04-Oct-2021	IGEA Pharma N.V.: GBC AG TO START EQUITY COVERAGE OF IGEA PHARMA	IGEA Pharma N.V.
04-Oct-2021	PharmiWeb.Jobs Welcomes Mettler-Toledo	PharmiWeb.Jobs
04-Oct-2021	Thermo Fisher Scientific Opens Biologics Manufacturing Site in Lengnau, Switzerland	Thermo Fisher Scientific
04-Oct-2021	SYNLAB expands partnership with Feedtrail to gain real-time patient and customer feedback	SYNLAB AG
04-Oct-2021	Turnaround after successful restructuring paves way for capital increase starting today - Attractive offer for shareholders and new investors	aap Implantate AG
04-Oct-2021	COSMO PHARMACEUTICALS N.V. LAUNCHES PUBLIC EXCHANGE OFFER TO ACQUIRE CASSIOPEA S.P.A.	Cosmo Pharmaceuticals N.V.
04-Oct-2021	COSMO PHARMACEUTICALS N.V. LAUNCHES PUBLIC EXCHANGE OFFER TO ACQUIRE CASSIOPEA S.P.A.	Cassiopea S.p.A.
01-Oct-2021	Formycon and Bioeq announce File Acceptance for FYB201, a biosimilar candidate to Lucentis(R) (ranibizumab) by the U.S. Food and Drug Administration (FDA)	Formycon AG
01-Oct-2021	THEA RE-LAUNCH TV ADVERT FOR FANS OF GRITTY DRAMAS	M&F Health Communications Ltd
01-Oct-2021	Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) of the Regulation (EU) No 596/2014 and Art. 2 (1) of the Delegated Regulation (EU) 2016/1052	Drägerwerk AG & Co. KGaA
01-Oct-2021	Heidelberg Pharma AG Announces Adjustment of Guidance	Heidelberg Pharma AG
01-Oct-2021	Gallenkamp Launches Smart New Website and Brochure	Gallenkamp
01-Oct-2021	New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis	Sanofi
01-Oct-2021	Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria	Novartis
01-Oct-2021	Santhera will Publish its Interim Report for the First Half of 2021 on October 15, 2021	Santhera
01-Oct-2021	Announcing the inaugural Advanced Therapies Integrates event - enabling strategic debate and collaboration across the Advanced Therapies and Medicinal Products (ATMP) Industry	Life Science Integrates (LSI)